🌟 Product Overview
Baloxavir (CAS: 1985605-59-1) is a groundbreaking third-generation antiviral agent renowned for its efficacy against influenza A and B strains, including oseltamivir-resistant variants and avian flu subtypes (e.g., H7N9, H5N1)3. As a single-dose oral medication, it inhibits viral replication by targeting the cap-dependent endonuclease complex, offering rapid symptom relief and reduced transmission risk23. Widely utilized in pharmaceuticals, clinical therapy, and public health initiatives, it is a critical tool for global influenza management.
✅ Key Advantages
🔹 Single-Dose Efficacy: Reduces treatment duration with 48-hour symptom improvement in 90% of cases3.
🔹 High Purity: ≥99% HPLC/GC-certified quality, ensuring optimal therapeutic outcomes4.
🔹 Stability: Stable under ambient or storage conditions for long-term use14.
🔹 Structural Verification: Supported by NMR, MS, and chromatographic data for batch consistency1.
📌 Applications
• Pharmaceutical Manufacturing: Active ingredient in antiviral formulations.
• Clinical Use: Approved for adults and pediatric influenza treatment.
• Public Health: Prophylaxis during avian flu outbreaks and pandemics3.
🔍 Quality Certifications
• Complies with USP/EP standards for impurities and stability.
• Batch-specific COA, including purity (≥99%), residual solvents, and heavy metals14.
• Rigorous testing via HPLC (>95% purity default), NMR, and mass spectrometry1.
📈 Market Trends
The global antiviral drug market is projected to grow at 6.8% CAGR (2025-2030), driven by rising influenza incidence and drug resistance3. Baloxavir, endorsed by FDA and PMDA, dominates 22% of the anti-flu segment, with increasing adoption in Asia-Pacific and North America3.
China
